Rati F, Mourad B, Arun F. Role of p21WAF1 in the cellular response to UV [J]. Cell Cycle, 2004,3(2):134-137.
[2]
Gartel AL, Tyner AL. Transcriptional regulation of the p21WAF1/CIP1 gene [J]. Exp Cell Res, 1999,246(2):280-289.
[3]
Anna SK, Claire M, Banwell MJ, et al. Regulation of the human p21WAF1/CIP1 gene promoter via multiple binding sites for p53 and the vitamin D3 receptor [J]. Nucleic Acids Research,2006,34(2):543-554.
[4]
Michieli P,Chedid M,Lin D,et al.Induction of WAF1/CIP1 by a p53-independent pathway[J].Cancer Res,1994,54:331-339.
[5]
Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanism, and consequences [J]. Cancer Res,2005,65(10):3980 - 3985.
[6]
Agorastos T,Lambropoulos AF,Constantinidis TC,et al. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women[J].Cancer Prev,2000,9:113-118.
[7]
Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologicall [J]. Mol Cell Bio,1999,19:1092-1100.
[8]
Pim D, Banks L. p53 polymorphic variants at codon 72 exerts different effects on cell cycle progression [J]. Cancer,2004,108(2):196-199.
[9]
Dumont P, Leu JI, Della Pietra AC, et al.The codon 72polymorphic variants of p53 have markedly different apoptotic potential [J]. Nat Genet,2003,33(3):357-365.
[10]
Shao Y, Tan W, Zhang S. p53 gene codon 72 polymorphism and risk of esophageal squamous cell carcinoma: a case/control study in a Chinese population [J]. Diseases of the Esophagus, 2008,21(2):139-145.
[11]
Buyru N, Tigli H, Dalay N. p53 codon 72 polymorphism in breast cancer [J]. Oncol Rep,2003, 10(3):711-714.
[12]
Kawaguchi H, Ohno S, Araki K, et al.p53 polymorphism in human papillomavirus-associated esophageal cancer [J]. Cancer Res,2000,60:2753-2755.
[13]
Zehbe I,Voglino G,Wilander E,et al.codon72 polymorphism of p53 and its association with cervical cancer [J]. Lancet,2001,354:218-219.
[14]
Jee SH, Lee JE, Park JS.Polymorphism of codon 72 of p53 and environmental factors in the development of cervical cancer [J]. Gynecol Obstet,2003,80:69-70.
[15]
Peller S, Halperin R, Schneider D, et al.Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma[J]. Oncol Rep,1999,6:193-197.
[16]
Buller RE, Sood A, Fullenkamp C, et al.The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis[J]. Cancer Gene Ther,1997,4:239-245.
[17]
Garcia-Closas M, Kristensen V, Langerod A, et al.Common genetic variation in Tp53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer [J].Cancer,2007,121(11):2532-2538.
Peixoto D,Hsin S,Snijders P,et al.Absence of association between HPV DNA, Tp53 codon 72 polymorphism, and risk of oesophageal cancer in a high risk area of China [J]. Cancer Lett,2001,162:231-235.
Chedid M, Michieli P, Lengel C, et al. A single nucleotide substitution at codon31(Ser/Arg)defines a polymorphism in a highly conserved region of the p53 inducible gene p21WAF1/CIP1 [J]. Oncogene,1994,9(10):3021-3024.
[22]
Pietsch EC, Humbey O, Murphy ME.Polymorphisms in the p53 pathway [J]. Oncogene,2006,25(11): 1602-1611.
[23]
Terry LA, Boyd J, Alcorta D, et al.Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines [J]. Mol Carcinog,1996,4(3):221-228.
[24]
Su L, Sai Y, Fan R, et al.p53(codon 72)and p21(codon31)polymorphisms after in vivo mRNA expression of p21 [J]. Mol Carcinog,1996,16(4):221-228.
[25]
Harima Y, Sawada S, Nagata K, et al.Polymorphism of the WAF1 gene is related to susceptibility to cervical cancer in Japanese women [J]. Int J Mol Med,2001,7(3):261-264.
[26]
Facher EA, Becich MJ, Deka A, et al.Association between human cancer and two polymorphisms occurring together in the p21WAF1/CIP1 cyclin-dependent kinase inhibitor gene [J]. Cancer,1997,79(12):2424-2429.
[27]
Hachiya T, Kuriaki Y, Ueoka Y, et al.WAF1 genotype and endometrial cancer susceptibility [J]. Gynecol Oncol,1999,72(2):187-192.
[28]
Chen WC, Wu HC, Hsu CD, et al.p21 gene codon 31 polymorphism is associated with bladder cancer [J]. Urol Oncol,1999,72(2)63-66.
[29]
Wenjun Yang, Qi Qi, Heng Zhang, et al. p21WAF1/CIP1 Polymorphisms and Risk of Esophageal Cancer [J]. Ann Surg Oncol,2010,17(5):1453-1458.
[30]
Bond GL, Hu W, Bond EE, et al.A single nucleotide polymorphism in the MDM2 promoter attenuates the p53tumor suppressor pathway and accelerates tumor formation in humans[J]. Cell,2004, 119(5):591-602.
[31]
Hidetoshi K,Shinji O,Koshi A,et al.p53 Polymorphisms in Human Papillomavirus-associated Esophageal Cancer[J]. Cancer Res,2000,60(11):2753-2755.
[32]
Hu Z, Ma H, Lu D, et al.Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population [J].Int Cancer,2006,118(5):1275-1278.
[33]
Ma H, Hu Z, Zhai X, et al.Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population [J]. Cancer Lett,2006,240(2):261-267.
[34]
Campbell IG, Eccles DM, Choong DY. No association of theMDM2 SNP309 polymorphism with risk of breast or ovarian cancer [J]. Cancer Lett,2006,240(2):195-197.
[35]
Bougeard G, Beart-Desurmont S, Tournier I, et al.Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumor onset in Li-Fraumeni syndrome [J]. Med Genet,2006,43(6):531-539.
[36]
Alhopuro P, Ylisaukko-Oja SK, Koskineni WJ, et al.The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck [J]. Med Genet,2005,42(9):694-698.
[37]
Eymin B, Gazzeri S, Brambilla C,et al.MDM2 overexpression and p14inactivation are two mutually exclusive events in primary human lung tumors [J]. Oncogene,2002,21(17):2750-2761.
[38]
Volgelstein B, Lane D, Levine A. Surfing the p53 network[J].Nature, 2000, 408:307-310.
[39]
Levine AJ. p53, the cellular gatekeeper for growth and division[J]. Cell,1997, 88(3):323-331.
[40]
I ssaeva N, Friedler A, Bozko P, et al. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide [J]. PNAS, 2003, 100(23):13303-13307.
[41]
Dey A, Verma CS, Lane DP.Modulation of p53 degradation as a therapeutic approach [J]. Cancer,2008,98(1):4-8.
[42]
Meulmeester E, Jochemsen AG. p53: a guide to apoptosis[J]. Curr Cancer Drug Targets, 2008, 8(2):87-97.
[43]
Momnad J,Zmabetti GP,Olson DC,et al. The MDM2 oncogene product Forms a complex with the p53 protein and inhibition p53-mediated transactivation [J]. Cell,1992,69(7):1237-1245.
[44]
Hong Shi, Tan SJ, Zhong H, et al. Winter Temperature and UV Are Tightly Linked to Genetic Changes in the p53 Tumor Suppressor Pathway in Eastern Asia[J]. Am J Hum Genet,2009,84(4): 534？541.
[45]
Wei-Guo Z, Theresa H, Yang K, et al. 5-aza2-deoxycytidine activates the p53/p21WAF1/CIP1 pathway to inhibit cell proliferation[J]. J Biol Chem,2004,279(15):15161-15166.
[46]
Fakhazradeh SS,Tursko SP,George DL,et al. Tmuorigenic Potential Associated with enhanced expression of a gene that is amplified in a mouse tumor cell line [J].EMBO J,1991,10(6):1565-1569.
[47]
Watanable T, Ichikawa A, Saito H, et al. Overexpression of the MDM2 oncogene in leukemia and lymphoma[J]. Leuk Lymphoma,1996,21(5-6):391-397.
[48]
Alarcon-Vargas D, Ronai Z. p53-MDM2 the affair that never ends [J]. Carcinogenesis,2002, 23(4):541-547.
[49]
El-Deiry WS,Tokino T,Velculescu VE,et al. WAF1, a potential mediator of p53 tumor suppression[J].Cell,1993,75(4):817-825.
[50]
Michieli P,Chedid M,Lin D,et al.Induction of p21WAF1/CIP1 by a p53-independent pathway[J].Cancer Ras,1994,54:331-339.
